Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence

Moataz Seyam, James M. Neuberger, Bridget K. Gunson, Stefan G. Hübscher – 16 March 2007 – Liver allograft cirrhosis is a relatively uncommon complication of liver transplantation. Most cases can be attributed to disease recurrence, particularly recurrent hepatitis C. Little is known about the frequency, etiology, and natural history of liver allograft cirrhosis occurring without evidence of recurrent disease. The aim of the present study was to review the clinicopathological features in this group of patients.

A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation

Lorenzo Norberto, Lino Polese, Umberto Cillo, Francesco Grigoletto, Andrew K. Burroughs, Daniele Neri, Giacomo Zanus, Patrizia Boccagni, Patrizia Burra, Davide F. D'Amico – 16 March 2007 – Whether beta‐blockers (BB) or banding is the best therapy for primary prophylaxis of variceal bleeding is subject to debate. A randomized comparison between the 2 treatments was performed in candidates for liver transplantation (LT). A total of 62 patients with Child‐Turcotte‐Pugh B‐C cirrhosis and high risk varices received propranolol (31) or variceal banding (31).

Early indicators of prognosis in fulminant hepatic failure: An assessment of the Model for End‐Stage Liver Disease (MELD) and King's College Hospital Criteria

Radha K. Dhiman, Sanjay Jain, Uma Maheshwari, Ashish Bhalla, Navneet Sharma, Jasmina Ahluwalia, Ajay Duseja, Yogesh Chawla – 16 March 2007 – While King's Hospital Criteria (KCH) criteria are used worldwide, the Model for End‐Stage Liver Disease (MELD) is a more recently developed scoring system that has been validated as an independent predictor of patient survival in conditions for liver transplantation (LT). The aim of the present study was to compare MELD and KCH criteria with other early clinical prognostic indicators (CPI) in a cohort of patients with fulminant hepatic failure (FHF).

Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis

Philippe Ichai, Jean‐Charles Duclos‐Vallée, Catherine Guettier, Sonia Ben Hamida, Theresa Antonini, Valérie Delvart, Faouzi Saliba, Daniel Azoulay, Denis Castaing, Didier Samuel – 16 March 2007 – Immunosuppressive therapy, and particularly corticosteroids with or without azathioprine, can achieve a remission in more than 80% of patients with autoimmune hepatitis (AIH). By contrast, the usefulness of corticosteroid therapy in severe forms of AIH remains a subject of debate.

Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study

Luca S. Belli, Andrew K. Burroughs, Patrizia Burra, Alberto B. Alberti, Dimitrios Samonakis, Calogero Cammà, Luciano De Carlis, Ernesto Minola, Alberto Quaglia, Claudio Zavaglia, Marcello Vangeli, David Patch, Amar Dhillon, Umberto Cillo, Maria Guido, Stefano Fagiuoli, Alessandro Giacomoni, Omar A. Slim, Aldo Airoldi, Sara Boninsegna, Brian R. Davidson, Keith Rolles, Giovambattista Pinzello – 16 March 2007 – In recent years, a worsening outcome of hepatitis C virus (HCV)‐positive recipients and a faster progression of recurrent disease to overt cirrhosis has been reported.

Randomized comparison of long‐term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis

Rafael Bañares, Eduardo Moitinho, Ana Matilla, Juan Carlos García‐Pagán, José Luis Lampreave, Carlos Piera, Juan G. Abraldes, Alejandro De Diego, Agustín Albillos, Jaime Bosch – 7 March 2007 – Short‐term carvedilol administration is more powerful than propranolol in decreasing hepatic venous pressure gradient (HVPG) in cirrhotic patients, but induces arterial hypotension that may prevent its long‐term use in portal hypertensive patients. This study compared the HVPG reduction and safety of long‐term carvedilol and propranolol.

Hepatoma‐derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation

Hirayuki Enomoto, Kenya Yoshida, Yoshihiko Kishima, Taisei Kinoshita, Mitsunari Yamamoto, Allen D. Everett, Atsushi Miyajima, Hideji Nakamura – 7 March 2007 – Hepatoma‐derived growth factor (HDGF) is a heparin‐binding protein, which has been purified from the conditioned media of HuH‐7 hepatoma cells. Recent studies have suggested the involvement of HDGF in development of the kidney and cardiovascular systems. In the present study, we investigated the possibility that HDGF was also involved in liver development.

Hepatitis C virus and lymphomagenesis: Another piece of evidence

O Hermine, F Lefrere, Jp Bronowicki, X Mariette, K Jondeau, V Eclache‐Saudreau, B Delmas, F Valensi, P Cacoub, C Brechot, B Varet, X Troussard, Francesco Negro – 7 March 2007 – Some epidemiologic studies suggest a link between hepatitis C virus (HCV) infection and some B‐cell non‐Hodgkin's lymphomas. We undertook this study after a patient with splenic lymphoma with villous lymphocytes had a hematologic response after antiviral treatment of HCV infection.

Subscribe to